Noah M. Hahn, MD, has been selected as Associate Professor of Oncology and Urology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore. Before joining Johns Hopkins, Dr. Hahn was the Director of the Genitourinary Medical Oncology Program at Indiana University. He is an experienced clinical investigator and has led the Hoosier Oncology Group since 2009. Dr. Hahn is a member of the Bladder Cancer Task Force for the NCI Genitourinary Cancer Steering Committee and is Co-Chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Genitourinary Committee.
Dr. Hahn’s research adds to areas of strength within the Cancer Center—evaluating epigenetic and immunologic strategies in bladder cancer and conducting trials of new agents in early bladder cancer. He will provide outpatient care, attend on the oncology inpatient service, and staff outpatient fellow clinics as well as grow and expand the Bladder Cancer Multi-Disciplinary Clinic.
Patrick Forde, MB, BCh, has been appointed an Instructor of Oncology at Johns Hopkins Kimmel Cancer Center. Dr. Forde recently completed his medical oncology fellowship at the Kimmel Cancer Center at Johns Hopkins. He is interested in developing a translational and clinical investigation program focused on lung cancer with a primary research interest in immunotherapy within our Upper Aerodigestive Program at the Kimmel Cancer Center at Johns Hopkins.
Dr. Forde earned his MB, BCh, BAO, from the Royal College of Surgeons in Ireland and completed his Internal Medicine internship at Beaumont Hospital, in Dublin, Ireland. After residencies in internal medicine and hematology at Connolly Hospital, Dublin, Ireland, as well as Adelaide and Meath Hospital, in Dublin, Ireland, Dr. Forde completed a medical oncology fellowship at the Royal College of Physicians of Ireland. While a fellow at the Johns Hopkins Kimmel Cancer Center, he was involved in the development of a clinical trial of single-agent preoperative anti-PD-1 antibody (Nivolumab) in resectable stage II/IIIA NSCLC.
Rally Foundation Announces Grant
Rally Foundation for Childhood Cancer Research, a national non-profit organization, has awarded a $50,000 Rally for Research grant to Donald Small, MD, PhD, to support childhood leukemia research. This grant is cofunded with The Truth 365, a non-profit organization dedicated to raising awareness and the critical funds needed for childhood cancer research, as well as uniting the childhood cancer community.
“The money from the Rally Foundation will enable us to carry out experiments to try to improve treatments for one of the most deadly pediatric leukemia, FLT3 mutant AML” said Dr. Small. “In this era of challenging funding from the NIH we are grateful to the Rally Foundation for these funds.” Dr. Small is Director, Pediatric Oncology Division of the Sidney Kimmel Comprehensive Cancer Center. ■
